Market Overview The US Growth Hormone Deficiency Clinical Trials Market was valued at approximately USD 530 million in 2023 and is projected to reach nearly USD 772 million by 2030, expanding at a CAGR of 5.52% from 2024 to 2030. The market is being supported by increasing clinical research activity, advancements in growth hormone therapies, rising awareness of growth hormone deficiency...